Balyasny Asset Management
PFE icon

Balyasny Asset Management’s Pfizer PFE Stock Holding History

Balyasny Asset Management’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.6M Buy
895,500
+171,800
+24% +$4.49M 0.03% 686
2026
Q1 		$20.3M Sell
723,700
-146,700
-17% -$3.91M 0.03% 685
2025
Q4 		$21.7M Buy
870,400
+298,700
+52% +$7.53M 0.03% 668
2025
Q3 		$14.6M Sell
571,700
-1,350,200
-70% -$33.3M 0.02% 867
2025
Q2 		$46.6M Buy
1,921,900
+1,455,300
+312% +$33.9M 0.07% 358
2025
Q1 		$11.8M Buy
466,600
+270,500
+138% +$7.08M 0.02% 822
2024
Q4 		$5.2M Sell
196,100
-52,200
-21% -$1.42M 0.01% 1262
2024
Q3 		$7.19M Sell
248,300
-67,000
-21% -$1.95M 0.01% 1104
2024
Q2 		$8.82M Sell
315,300
-539,400
-63% -$14.9M 0.02% 935
2024
Q1 		$23.7M Sell
854,700
-109,200
-11% -$3.03M 0.04% 550
2023
Q4 		$27.8M Sell
963,900
-180,400
-16% -$5.45M 0.05% 482
2023
Q3 		$38M Buy
1,144,300
+29,300
+3% +$1.04M 0.08% 350
2023
Q2 		$40.9M Buy
1,115,000
+795,900
+249% +$31M 0.09% 301
2023
Q1 		$13M Sell
319,100
-125,000
-28% -$5.4M 0.03% 675
2022
Q4 		$22.8M Buy
444,100
+19,100
+4% +$916K 0.06% 436
2022
Q3 		$18.6M Sell
425,000
-2,501,000
-85% -$122M 0.06% 450
2022
Q2 		$153M Buy
2,926,000
+2,400,000
+456% +$122M 0.5% 19
2022
Q1 		$27.2M Buy
526,000
+476,000
+952% +$24.7M 0.09% 324
2021
Q4 		$2.95M Buy
+50,000
New +$2.48M 0.01% 1049
2021
Q3 		– Sell
-931,600
Closed -$36.5M – 2314
2021
Q2 		$36.5M Buy
931,600
+541,600
+139% +$21.1M 0.17% 139
2021
Q1 		$14.1M Buy
390,000
+280,000
+255% +$9.94M 0.07% 380
2020
Q4 		$4.05M Buy
+110,000
New +$4.03M 0.02% 710
2015
Q2 		– Sell
-26,350
Closed -$870K – 1278
2015
Q1 		$870K Buy
+26,350
New +$838K 0.01% 692

Other funds holding PFE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Balyasny Asset Management's PFE Position: Q2 2026 in Review

Balyasny Asset Management reduced its Pfizer (PFE) stake by 92% in Q2 2026, selling an estimated $251M and leaving 857,605 shares worth $20.7M. The position accounts for 0.03% of the portfolio, ranked #703.

Balyasny Asset Management first reported a position in PFE in Q4 2014 and has held it in 42 quarters since. The position peaked at $294M in Q1 2026. 2,827 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Balyasny Asset Management held 857,605 shares of Pfizer worth $20.7M as of Q2 2026.
  • Balyasny Asset Management sold 9,613,783 Pfizer shares in Q2 2026, an estimated $251M.
  • Pfizer made up 0.03% of Balyasny Asset Management's portfolio in Q2 2026, its #703 holding.
  • Balyasny Asset Management first reported a position in Pfizer in Q4 2014 and has held it in 42 quarters since.
  • Balyasny Asset Management's Pfizer position peaked at $294M in Q1 2026.
  • 2,827 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.